Cantor Fitzgerald Has Weak Estimate for ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Ascendis Pharma A/S in a research report issued on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings of ($3.28) per share for the year, down from their prior estimate of ($1.81). Cantor Fitzgerald currently has a “Overweight” rating and a $254.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2026 earnings at $1.92 EPS.

Other research analysts also recently issued research reports about the company. Wells Fargo & Company reissued an “overweight” rating and issued a $295.00 price target (up previously from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Wolfe Research initiated coverage on Ascendis Pharma A/S in a research report on Tuesday. They issued a “peer perform” rating and a $255.00 target price on the stock. Raymond James Financial began coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price target for the company. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $256.60.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $217.13 on Monday. The firm has a 50-day moving average of $202.37 and a two-hundred day moving average of $185.47. The stock has a market cap of $13.40 billion, a P/E ratio of -42.08 and a beta of 0.44. Ascendis Pharma A/S has a 1-year low of $118.03 and a 1-year high of $223.18.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $290.24 million for the quarter, compared to analysts’ expectations of $246.91 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $26,000. Compagnie Lombard Odier SCmA bought a new position in Ascendis Pharma A/S in the second quarter worth about $39,000. First Horizon Advisors Inc. bought a new position in Ascendis Pharma A/S in the second quarter worth about $41,000. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 83 shares during the period. Finally, Brooklyn Investment Group grew its holdings in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.